This company has been marked as potentially delisted and may not be actively trading. Tenzing Acquisition (TZAC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock TZAC vs. ORGS, AEZS, CPHI, NRBO, MTNB, CANF, NBY, SPRB, AFMD, and GRAYShould you be buying Tenzing Acquisition stock or one of its competitors? The main competitors of Tenzing Acquisition include Orgenesis (ORGS), Aeterna Zentaris (AEZS), China Pharma (CPHI), NeuroBo Pharmaceuticals (NRBO), Matinas Biopharma (MTNB), Can-Fite BioPharma (CANF), NovaBay Pharmaceuticals (NBY), Spruce Biosciences (SPRB), Affimed (AFMD), and Graybug Vision (GRAY). Tenzing Acquisition vs. Its Competitors Orgenesis Aeterna Zentaris China Pharma NeuroBo Pharmaceuticals Matinas Biopharma Can-Fite BioPharma NovaBay Pharmaceuticals Spruce Biosciences Affimed Graybug Vision Tenzing Acquisition (NASDAQ:TZAC) and Orgenesis (NASDAQ:ORGS) are both small-cap pharmaceutical preparations industry companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability. Do institutionals & insiders have more ownership in TZAC or ORGS? 60.9% of Tenzing Acquisition shares are held by institutional investors. Comparatively, 22.6% of Orgenesis shares are held by institutional investors. 37.5% of Tenzing Acquisition shares are held by insiders. Comparatively, 5.7% of Orgenesis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor TZAC or ORGS? In the previous week, Tenzing Acquisition's average media sentiment score of 0.00 equaled Orgenesis'average media sentiment score. Company Overall Sentiment Tenzing Acquisition Neutral Orgenesis Neutral Is TZAC or ORGS more profitable? Tenzing Acquisition has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Tenzing Acquisition's return on equity.Company Net Margins Return on Equity Return on Assets Tenzing AcquisitionN/A -13.32% -1.36% Orgenesis -3,827.81%N/A -130.18% Which has better valuation & earnings, TZAC or ORGS? Tenzing Acquisition has higher earnings, but lower revenue than Orgenesis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTenzing AcquisitionN/AN/A$620KN/AN/AOrgenesis$662K9.64-$55.36MN/AN/A Which has more risk & volatility, TZAC or ORGS? Tenzing Acquisition has a beta of 0.01, meaning that its share price is 99% less volatile than the S&P 500. Comparatively, Orgenesis has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. SummaryTenzing Acquisition beats Orgenesis on 5 of the 8 factors compared between the two stocks. Get Tenzing Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for TZAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TZAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TZAC vs. The Competition Export to ExcelMetricTenzing AcquisitionPharmaceutical Preparations Industry SectorNASDAQ ExchangeMarket Cap$1.85M$812.96M$2.01B$9.05BDividend YieldN/A4.84%13.71%3.99%P/E RatioN/A1.1512.1020.26Price / SalesN/A230.412,026,446.21119.26Price / Cash143.1023.4456.1028.59Price / Book0.376.323.755.65Net Income$620K-$27.99M-$302.05M$249.15M Tenzing Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TZACTenzing AcquisitionN/A$0.36-6.5%N/A-66.4%$1.85MN/A0.00N/AGap UpHigh Trading VolumeORGSOrgenesisN/A$1.53+3.7%N/AN/A$7.34M$662K0.00150Gap DownAEZSAeterna ZentarisN/A$3.40+1.8%N/A-28.2%$6.10M$2.37M-0.2320CPHIChina Pharma0.3424 of 5 stars$1.81+1.1%N/A-92.9%$5.90M$4.30M0.00250NRBONeuroBo PharmaceuticalsN/A$0.64+2.1%N/A-85.7%$5.54MN/A0.0010News CoverageGap UpMTNBMatinas BiopharmaN/A$0.90+1.5%N/AN/A$4.59MN/A-0.1930CANFCan-Fite BioPharma3.2959 of 5 stars$1.04-1.0%$14.00+1,246.2%-57.9%$3.68M$674K-0.588NBYNovaBay Pharmaceuticals2.028 of 5 stars$0.61+5.0%$0.85+39.6%-70.7%$3.54M$9.78M-0.0130Gap UpSPRBSpruce Biosciences2.1655 of 5 stars$0.07-1.9%$1.75+2,361.3%-87.3%$3.00M$4.91M-0.0820News CoverageGap DownAFMDAffimed2.9524 of 5 stars$0.18-34.9%$3.62+1,895.9%-96.4%$2.92M$877K0.00200Gap DownHigh Trading VolumeGRAYGraybug VisionN/A$1.60+11.9%N/A-62.2%$2.51MN/A-0.9227High Trading Volume Related Companies and Tools Related Companies Orgenesis Competitors Aeterna Zentaris Competitors China Pharma Competitors NeuroBo Pharmaceuticals Competitors Matinas Biopharma Competitors Can-Fite BioPharma Competitors NovaBay Pharmaceuticals Competitors Spruce Biosciences Competitors Affimed Competitors Graybug Vision Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TZAC) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredGold buying hits 4-year highThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenzing Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenzing Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TZAC Stock Alerts